“Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson’s disease. The US FDA this week approved the sale of the treatment, which harnesses innovative technology to make managing the condition easier and more impactful, will be available towards the end of 2025.

The treatment, which will be sold under the name Onapgo, is essentially a subcutaneous – under the skin – device that allows for continuous infusion of the dopamine agonist apomorphine hydrochloride to reduce ‘off’ episodes. These episodes are periods during the day and night when lepodova medication wears off between doses and adverse motor-function symptoms (dyskensia) become amplified. In trial, Onapgo – formerly known as SPN-830 – significantly reduced these daily off episodes by an average of 2.47 hours, compared to the placebo treatment (0.58 hours).”

From New Atlas.